Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keen Hun Tai

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2013
Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancerJames W Denham, Allison Steigler, Keen-Hun Tai, et al.
Prostate Cancer|January 16, 2013
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 TrialAllison Steigler, James W Denham, David S Lamb, et al.
BMC Cancer|August 18, 2016
Nurse-led group consultation intervention reduces depressive symptoms in men with localised prostate cancer: a cluster randomised controlled trialPenelope Schofield, Karla Gough, Kerryann Lotfi-Jam, et al.
The Lancet. Oncology|March 29, 2011
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialJames W Denham, Allison Steigler, David S Lamb, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?James W Denham, Allison Steigler, Mahesh Kumar, et al.
Journal of Medical Imaging and Radiation Oncology|February 21, 2012
Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladderBenjamin R Hindson, Sandra L Turner, Jeremy L Millar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctionsAnthony V D'Amico, James W Denham, Juanita Crook, et al.
The Lancet. Oncology|August 2, 2017
Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialGillian M Duchesne, Henry H Woo, Madeleine King, et al.
The Lancet. Oncology|October 22, 2008
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trialJames W Denham, Allison Steigler, Chantelle Wilcox, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 17, 2016
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trialSwetha Sridharan, Allison Steigler, Nigel A Spry, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2013
Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancerJames W Denham, Allison Steigler, Keen-Hun Tai, et al.
Prostate Cancer|January 16, 2013
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 TrialAllison Steigler, James W Denham, David S Lamb, et al.
BMC Cancer|August 18, 2016
Nurse-led group consultation intervention reduces depressive symptoms in men with localised prostate cancer: a cluster randomised controlled trialPenelope Schofield, Karla Gough, Kerryann Lotfi-Jam, et al.
The Lancet. Oncology|March 29, 2011
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialJames W Denham, Allison Steigler, David S Lamb, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?James W Denham, Allison Steigler, Mahesh Kumar, et al.
Journal of Medical Imaging and Radiation Oncology|February 21, 2012
Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladderBenjamin R Hindson, Sandra L Turner, Jeremy L Millar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2007
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctionsAnthony V D'Amico, James W Denham, Juanita Crook, et al.
The Lancet. Oncology|August 2, 2017
Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialGillian M Duchesne, Henry H Woo, Madeleine King, et al.
The Lancet. Oncology|October 22, 2008
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trialJames W Denham, Allison Steigler, Chantelle Wilcox, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 17, 2016
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trialSwetha Sridharan, Allison Steigler, Nigel A Spry, et al.
Pageof 6